intermune acquisition

Pfizers AstraZeneca interests are two-fold: the AstraZeneca portfolio/pipeline fills some holes that Pfizer has particularly in cancer immunotherapy and pulmonary disease; and, more importantly, a Pfizer acquisition of AstraZeneca could allow Pfizer to carry out an inversion where it could become a U.K. based company and thereby result in avoiding a great deal of U.S. corporate taxes. Esbriet, however, faces competition. As Roche CEO, Severin Schwan, said in the press release announcing the merger: While Roche was making this move, rumors have again surfaced that Pfizer will make another run at acquiring AstraZeneca. All rights reserved. The S&P also rose, gaining 0.64 percent to 2,001.04. View Corporate Tree. Earnout Amount has the meaning set forth in Section 1.9(a).. Earn-Out Amount shall have the meaning set forth in Section 4.3(a).. Earnout Period has the meaning set forth in Section 2.5(a)(iii).. Earnout Payment has the meaning set forth in Section 2.3(b).. Earn-Out Payment has the meaning set forth in Section 2.3(a).. Earn-Out Period has the meaning set . All Rights Reserved. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. The other seeks to make huge take-overs and then gain synergies by slashing costs, closing sites, and eliminating thousands of jobs. From a business standpoint, the AstraZeneca acquisition also makes great business sense. On September 6, 2022, ADT Inc. (ADT) and State Farm announced that State Farm has agreed to make a $1.2billion equity investment in ADT to acquire 133.3million shares of ADTs common stock at $9 a share. The acquisition adds to AbbVie's already comprehensive pipeline and strong growth prospects. 2022 - Market Business News. The Cravath team included partners Faiza J. Saeed and Ting S. Chen and associates Amanda R. Fenster, Jennifer L. Tanaka and Jennifer Uren on M&A matters; partner Michael L. Schler and associate Jay S. Gill on tax matters; partner Eric W. Hilfers and associate Julia L. Onorato on executive compensation and benefits matters; partner Christine A. Varney and associate Margaret Segall DAmico on antitrust matters; and partner David J. Kappos and associate Benjamin D. Landry on intellectual property matters. Market Business News - The latest business news. Consensus forecasts compiled by Thomson Reuters Pharma peg annual sales at greater than $1 billion in 2019 a nice addition to Roches stable of pulmonary compounds including Xolair (asthma) and Pulmozyme (cystic fibrosis). Roche has just announced the acquisition of the U.S. biotech company InterMune for $8.3 billion. It has also been developing a compoundcalled lebrikizumabfor severe asthma. This is Roche Holding's 13th transaction in the Life Science sector. Roche Holding has agreed to buy U.S. biotech company InterMune for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector. InterMune (NASDAQ: ITMN) shares shot up 35.49 percent to $72.89 after Roche (OTC: RHHBY) announced its plans to acquire InterMune for $74.00 per share in cash. The acquisition, which has been recommended by the boards of both companies, is the largest by Roche since 2009, when it . . The news of InterMune's acquisition by Roche has led to a rally in the biotech ETFs space. IPF is a deadly lung-scarring disease which affects 50,000 70,000 people in the U.S. and 80,000 to 110,000 in Europe. Opinions expressed by Forbes Contributors are their own. PsstTheres a Hidden Market for Six-Figure Jobs. Create Alert. Leju Holdings (NYSE: LEJU) was down, falling 4.73 percent to $17.54 after surging around 36.2% in the previous month. On August8, 2022, Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of lifechanging treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (Pfizer) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Burger King is in talks to acquire Tim Hortons (NYSE: THI). Analysts forecast InterMunes drug pirfenidone, which is still awaiting FDA approval, will generate about $1 billion a year. Dan Welch, 87990cbe856818d5eddac44c7b1cdeb8, Copyright 2022 Dow Jones & Company, Inc. All Rights Reserved, InterMune Says Lung Disease Drug Succeeds in Late-Stage Study, Get 15% off AE promo code with text alerts, Kohl's coupon - 30% off sitewide for Rewards members, Layoffs Hit Tech as Amazon, Lyft Warn of Downturn, Home Buyers Are Moving Farther Away Than Ever Before. As part of the all-cash Roche to acquire InterMune for $8.3bn - Pharma Advancement Schwan also offered Intermune the highest praise an acquirer can: he . Roche gains access to InterMune's lead drug Esbriet (pirfenidone), which treats idiopathic pulmonary fibrosis (IPF), a rare but fatal disease characterized by progressive loss of lung function. From August 2002 to January 2003, Mr. Welch served as Chairman and Chief Executive . Will Cellceutix (OTCMKTS:CTIX) Be A Roche Bolt On Acquisition ?This is a sweet meditation that I am echoing from Investors Hub.Certainly some Golden Apples in Pictures of Silver.Thanks to. Cramer: Behind Roche's InterMune Deal The acquisition is a symbol of a much bigger trend. The Swiss company has only two such drugs on sale in the U.S.: Xolair for severe and allergic asthma and Pulmozyme for cystic fibrosis. Sales of new US homes declined 2.4% to an annual rate of 412,000 in July. Tim Hortons (NYSE: THI) shares were also up, gaining 19.68 percent to $75.21 following the confirmation of merger talks. After the equity investment and tender offer close, State Farm will own approximately 15% of ADT. Roche will fully acquire InterMune for US$ 74.00 per share in an all-cash transaction corresponding to a total transaction value of US$ 8.3 billion. Integral to our story is our culture. Roche has agreed to acquire InterMune at $74 per share in an all-cash transaction, a price 38 percent higher than the company's $53.80 closing price on Friday. On August 24, 2014, Roche Holding acquired life science company InterMune for 8.3B USD Acquisition Highlights. In InterMune, Roche found a suitable target. InterMune's $8.9 Billion Acquisition by Roche August 25, 2014 On August 24, 2014, Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to acquire InterMune at a price of US$74.00 per share in an allcash transaction with a total equity value of US$8.9 billion. IPF is a deadly lung-scarring disease which affects 50,000 70,000 people in the U.S. and 80,000 to 110,000 in Europe. We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease," he said. However, economists were expecting a reading of 58.00. The takeover would allow the Swiss company to expand its presence in the treatment of respiratory disorders, one of the world's biggest drug markets. InterMune General Information. The eurozones STOXX 600 gained 1.10 percent, the Spanish Ibex Index climbed 1.81 percent, while Italys FTSE MIB Index surged 2.3 percent. The all-cash deal values InterMune at $74 per share, or a 38% premium to Friday's . The Californian company has just one product in a therapeutic area that will become much more competitive. InterMune is a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. Roche CEO, Severin Schwan, said regarding the transaction: We are very pleased that we reached this agreement with InterMune. Innovation Word Cloud. Datamonitors' InterMune, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by InterMune, Inc. since January 2007. The acquisition comes as . We believe the $74 . I cover news on drugs and R&D in the pharma industry. Shares popped nearly 15% as. 2022 ") On August 27, Zacks named the company as one of two "attractive takeover targets." (See "Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As.") Conversely, the Pfizer folks are again wondering if another major acquisition is imminent and whether they will again be threatened with the loss of their jobs. Contingent acquisition payments of up to an additional $53.5 million would be made by InterMune only if positive Phase 3 data and registration in the United States and European Union are achieved. Meanwhile, Britain's AstraZeneca rejected a $118bn . Approval in the U.S., he said, "would mean for the first time there is a treatment for these patients.". The driver for Roche was to gain access to InterMunes drug, pirfenidone (trade name, Esbriet), which is already approved in Canada and Europe for idiopathic pulmonary fibrosis (IPF). Resources. BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche and InterMune, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a. Although Esbriet hasn't been approved in the U.S., it is as close to a sure bet as Roche could ask for, given the drug's approval in Europe and Canada. Roche acquired Esbriet six years ago with its $8.3 billion Intermune acquisition, but the Basel-based drugmaker has since written down Intermune's value by billions as Esbriet's $1.1 billion in. Phone Number (415) 466-2200. Its last big deal was in 2009, when it paid $46.8 billion for the stake in biotech Genentech that it didn't already own. The acquisition of InterMune, a Brisbane, California-based biotech company focused on the research, development and commercialisation of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Cravath is representing RWE, alongside Hengeler Mueller, in connection with the transaction. The acquisition is a symbol of a much bigger trend..ITMN. Our offer provides significant value to InterMunes shareholders and this acquisition will complement Roches strengths in pulmonary therapy. The new company would be headquartered in Canada. Last year, AstraZeneca PLC agreed to pay up to $1.15 billion for Pearl Therapeutics and its drug for a lung condition called chronic obstructive pulmonary disease, or COPD. The disease tends to attack middle-aged and older adults. The Dallas Fed general business activity index fell to 7.10 in August, versus a prior reading of 12.70. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive . Forgot password ? The Brisbane, Calif.-based company has one product, pirfenidone, a treatment for idiopathic pulmonary fibrosis (IPF), a progressive and ultimately fatal lung disease. Goldman Sachs calculated and analyzed the acquisition premia paid in mergers and acquisitions transactions in the biotechnology industry involving publicly traded targets announced since May 2010 where the consideration paid implied an enterprise . The InterMune purchase, together with bolt-on acquisitions totalling USD2.5bn (incl. The preliminary reading of the Markit services PMI fell to 58.50 in August, versus a prior reading of 60.80. The pricing reflects the value the medicine brings, Mr. Welch said. In connection with State Farms equity investment, ADT will be commencing a selftender offer for up to 133.3million shares of its outstanding common stock and Class B common stock at $9 per share, to be funded by the proceeds from the State Farm equity investment. A decision on nintedanib is expected in February. For InterMune, located in Brisbane, Calif., the deal marks a turnabout from several near-death experiences since its formation a dozen years ago. Browse. Meanwhile, top decliners in the sector included Greif (NYSE: GEF), down 5.8 percent, and Endeavour Silver (NYSE: EXK), off 3.2 percent. This table shows a brief introduction of acquisition situation of the company and its subsidiaries respectively. Drugs treating respiratory conditions like asthma generate about $33 billion in world-wide sales each year, according to EvaluatePharma. Swiss drugmaker Roche has signed a definitive merger agreement to acquire InterMune for around $8.3bn. milestone payments), takes Roche's cumulative announced acquisition spend so far in 2014, to USD10.8bn, which will be financed by a combination of cash, commercial paper and bond issuance. Under terms of the acquisition agreements, InterMune has made total upfront payments of $13.5 million. The Swiss drugmaker. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic. Andrew Morse in Zurich contributed to this article. InterMune (NASDAQ: ITMN) shares shot up 35.49 percent to $72.89 after Roche (OTC: RHHBY) announced its plans to acquire InterMune for $74.00 per share in cash. Saturday, April 09, 2022. . Our offer provides significant value to InterMunes shareholders and this acquisition will complement Roches strengths in pulmonary therapy., We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease.. Esbriet aims to treat a lung-scarring condition called idiopathic pulmonary fibrosis, which currently lacks an approved therapy in the U.S. Pharmaceutical executives look for such opportunities because companies can charge high prices for new drugs involving poorly treated diseases. Contracts. Attorney Advertising. Additionally, State Farm will commit $300million to an opportunity fund to support product and technology innovation, customer growth and marketing, and Google has separately agreed to commit an incremental $150million, raising its total success fund commitment to $300million. As the tissue gets thicker it becomes more difficult for the lungs to move oxygen into the bloodstream. The Pfizer major acquisition strategy appears to have become a core of its growth plan. The acquisition represents a triumph for InterMune after a history of travails. From September 2003 until its acquisition by Roche Holdings in September 2014, Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a biotechnology company. Heres How to Get In. Roche has agreed to pay $8.3 billion in cash to acquire InterMune. The transaction values Pharmacyclics at approximately $21 billion and was approved by the Boards of Directors of both companies. On October 1, 2022, RWE AG (RWE), a leading renewable energy company, signed a purchase agreement with Con Edison, Inc. to acquire all shares in Con Edison Clean Energy Businesses, Inc., a leading operator and developer of renewable energy plants in the United States, for a purchase price based on an enterprise value of $6.8billion. This is Roche Holding's 10th transaction in the United States. The medication has been approved for idiopathic pulmonary fibrosis (IPF) in the European Union and Canada, where it is marketed as Esbriet. Roche has agreed to pay $8.3 billion in cash to acquire InterMune. We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease.. LONDON/ZURICH (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the. InterMune Agreement means the Product Acquisition Agreement by and between Seller and InterMune, dated November 28, 2005. Contact Email [email protected]. Silver traded down 0.43 percent Monday to $19.38, while copper rose 0.29 percent to $3.23. Some analysts estimate Esbriet could have more than $1 billion in yearly sales world-wide. InterMune has been charging about $40,000 a year per patient outside the U.S., according to In 2019, we celebrated our bicentennial. Opinion: Your Duty as a Voter Is to Take the Election Seriously, Opinion: Don Bolduc May Pull Off an Upset in New Hampshire, Opinion: What to Expect in the 2022 Midterms, Opinion: Elon Musk Makes an Offer You Can Refuse, Putinisms: Vladimir Putins Top Six One Liners, Ukrainians Sift Through Debris; Civilians Urged to Leave Eastern Regions, WSJ Opinion: Mar-a-Lago and the Swamp's Obsession With Donald Trump, Opinion Journal: The Trump-Modi Friendship, Mortgages, Cars and Credit Cards: How Interest-Rate Hikes Are Hitting Americans' Wallets. Idiopathic pulmonary fibrosis generally affects middle-aged males and older adults. B.A., 1987, University of California, Berkeley, J.D., 1998, University of Chicago Law School, J.D., 1986, Georgetown University Law Center, B.A., 1977, State University of New York, Albany, J.D., 1990, University of California, Berkeley, School of Law, B.S., 1983, University of California, Davis, InterMunes $8.9Billion Acquisition by Roche, RWE AGs $6.8Billion Acquisition of Con Edison Clean Energy Businesses, ADTs $1.2Billion Equity Investment from State Farm, Texas Capital Banks $3.4Billion Sale of BankDirect Capital Finance to Truist, Global Blood Therapeutics $5.4Billion Acquisition by Pfizer. On August 24, 2014, Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to acquire InterMune at a price of US$74.00 per share in an allcash transaction with a total equity value of US$8.9billion. August 24, 2014, 2:08 PM By Ben Hirschler and Caroline Copley LONDON/ZURICH (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the. InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. | June 26, 2022 Rival drugmaker, Boerhinger Ingelheim has an IPF drug candidate called nintedanib, which the FDA is currently reviewing. LONDON Roche Holding said Sunday it would pay $8.3 billion for a California biotech firm that has yet to turn a profit on a new drug to treat a deadly lung diseasethe latest gamble by a. Midway through trading Monday, the Dow traded up 0.64 percent to 17,110.26 while the NASDAQ surged 0.63 percent to 4,566.93. Innovation Matrix. means the Product Acquisition Agreement by and between Seller and InterMune, dated November 28, 2005. Markets Open Higher; Burger King In Talks To Buy Tim Hortons, Oil Prices Fall; NetApp Upgraded At Needham. Roche and InterMune, Inc. announced that Roche's wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash The company's first compound failed. Analysts wonder whether the Roche InterMune acquisition is a wise move. The drug also could potentially treat other diseases marked by tissue scarring in the liver and kidney. As Roche CEO, Severin Schwan, said in the press release announcing the merger: We are very pleased that we reached this agreement with InterMune. Roche to Acquire InterMune for $8.3B August 25, 2014 Roche plans to acquire InterMune for $8.3 billion cash, in a deal that expands the buyer's respiratory product portfolio with the seller's. The press release goes on to say that Roche plans a smooth transition of InterMune employees and operations into the Roche organization. Over the weekend, we witnessed the latest sizable deal in the biotech sector go down with global pharmaceutical giant Roche ( RHHBY 0.26%) announcing it would pay $8.3 billion in cash, or $74 per. Startups with experimental lung drugs have attracted heavy deal interest not only because of the market's size but also because research is pointing the way to new and better treatments. (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector. Data Snapshot. "Our offer provides significant value to InterMune's shareholders and this acquisition will complement Roche's strengths in pulmonary therapy. Sample 1. In 2010, the FDA rejected Esbriet, whose chemical name is pirfenidone, asking for more data to prove effectiveness. Companies notched $87 billion in deals through June, more than all of last year and on pace to exceed the peak in recent years of $152 billion in 2009, according to EvaluatePharma. allowing it to absorb the InterMune acquisition at the current . Roche's offer of $74 a share represents a 38% premium over rather than boost its $6.7 billion offer. Those additional IP rights include patents that relate to TNF-alpha based activities of pirfenidone. Cravath is representing Texas Capital in connection with the transaction. Define InterMune Agreement. Qihoo 360 reported Q2 adjusted EPADS of $0.50 on revenue of $317.90 million. It is a serious incurable disease. Illumina Inc. Cravath is representing GBT in connection with the transaction. Greif (NYSE: GEF) shares tumbled 5.73 percent to $47.42 after the company cut its FY14 earnings forecast. BASEL, Switzerland Biotech company Roche will be acquiring research and pharmaceutical company InterMune for $8.3 billion, it announced over the weekend. Remember . According to the Basel-based drugmaker, the boards of both companies have approved the merger agreement. Swiss pharmaceutical company Roche has said it will acquire California-based biotechnology firm InterMune for $8.3 billion, in a deal that allows Roche to strengthen its respiratory therapy portfolio. closing share price on Friday of $53.80, and a 63% premium before takeover speculation surrounding the biotech started circulating this month. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4billion, including debt and net of cash acquired. Researchers aren't sure what causes it, though they believe genetics play a role. Most patients survive from 2 to 5 years after diagnosis. Cravath represented InterMune in connection with this transaction, which has been approved by the boards of InterMune and Roche and is expected to close in 2014. However, economists were expecting a reading of 12.80. The scar tissue is known as fibrosis. While Roche was making this move, rumors have again surfaced that Pfizer will make another run at acquiring AstraZeneca. Idiopathic pulmonary fibrosis, which affects about 100,000 people in the U.S., has been an especially daunting medical target. The Brisbane, Calif.-based firm has one product: pirfenidone, a treatment for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. One company is seeking bolt-ons to enhance its portfolio and capabilities. This offer represents a premium of 38% to InterMunes closing price on August22, 2014, and a premium of 63% to InterMunes unaffected closing price on August12, 2014. But over the past few years, Roches M&A strategy has focused on bolt-on acquisitions. Meanwhile, the German DAX rose 1.83 percent and the French CAC 40 surged 2.10 percent. which depends heavily on an aging asthma drug called Advair for sales, is launching two new therapies for COPD. How big a product can pirfenidone be? In 2012, Roche gave up a chance to buy gene-sequencing firm Burger King Worldwide (NYSE: BKW) is in talks to acquire Canadian doughnut chain Tim Hortons (NYSE: THI). Even before speculation about a takeover, InterMune's stock had roughly tripled in value in the first half of 2014 following better-than-expected results in the clinical testing of Esbriet. This is Roche Holding's 2nd largest (disclosed) transaction. 2014 Benzinga.com. the company's chief executive. Competition to make headway in the respiratory market has already been heating up. Positive trial results posted earlier this year lend hope for approval by the U.S. Food and Drug Administration as early as November. Scar tissue buildup in the lung becomes so thick that lungs have trouble supplying the brain and other organs with oxygen. Roches move is just the latest of a series of similar acquisitions over the past few months as it has spent about $2.5 billion for the purchases of Seragon Pharmaceuticals, Santaris, and Genia. Shares of Qihoo 360 Technology Co (NYSE: QIHU) were down 6.93 percent to $94.70 after the company reported Q2 results. InterMune ITMN shares shot up 35.49 percent to $72.89 after Roche RHHBY announced its plans to acquire InterMune for $74.00 per share in cash. The biotech sector had a strong run last week thanks mostly to Roche's agreement to acquire InterMune ( ITMN ) for a hefty $8.3 billion. A decision on that medication is expected in February 2015. Differing philosophies can also lead to differences in employee engagement. A Roche InterMune acquisition deal worth $8.3 billion has been agreed by the two companies. The company's products are approved for the treatment of patients with severe, malignant osteopetrosis and chronic granulomatous disease. The driver for Roche was to gain access to InterMune's drug, pirfenidone (trade name,. Pulmonary fibrosis is a disease in which deep lung tissue becomes thick and stiff, or scarred over time. said Sunday it would pay $8.3 billion for a California biotech firm that has yet to turn a profit on a new drug to treat a deadly lung diseasethe latest gamble by a pharmaceutical giant to buy its way into a lucrative corner of the industry. My guess is that Roche employees are heading to work on Monday feeling pretty good about their companys latest move. By Christian Nordqvist Published Aug 25, 2014 at 1:58 AM GMT A Roche InterMune acquisition deal worth $8.3 billion has been agreed by the two companies. ADVERTISEMENT Prosecutors say the defendants exfiltrated "approximately 10 gigabytes of confidential data from the Law Firm-1 email server" just days before. Roche says InterMune has other research programs exploring new pathways and targets that may ultimately provide better treatment options for patients with fibrotic diseases. While still under review by U.S. regulatory authorities, Roches acquisition signals its belief that pirfenidone will also gain U.S. approval. Roche InterMune acquisition deal worth $8.3 billion agreed. The Chicago Fed National Activity Index rose to 0.39 in July, versus economists expectations for a reading of 0.20. The disease is diagnosed in approximately 48,000 American patients annually. Based on 1 documents 1. In the acquisition, Roche will be. Cravath, Swaine & Moore LLP. The drug has been granted approval in both Canada and Europe and has sold. Leading the sector was strength from InterMune (NASDAQ: ITMN) and RTI Surgical (NASDAQ: RTIX). The Swiss multinational giant is willing to pay a high price for the Californian company that has a drug for idiopathic pulmonary fibrosis, which has not yet turned a profit. Zippia gives an in-depth look into the details of Intermune, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intermune. The InterMune acquisition is the largest since 2009 when Roche spent $46.8 billion to acquire the remaining 44% of Genentech. Under the terms of the transaction, AbbVie will pay $261.25 per share comprised of a mix of cash and AbbVie equity. Roche Holding AG signed a definitive agreement to acquire InterMune, Inc. for $8.1 billion in cash from Sofinnova Investment, Inc. and others on August 22, 2014. The Pfizer major acquisition strategy appears to have become a core of its growth plan. The Swiss multinational giant is willing to pay a high price for the Californian company that has a drug for idiopathic pulmonary fibrosis, which has not yet turned a profit. . However, the difference in the M&A strategies between Roche and Pfizer is pretty stark, particularly if you are in the R&D division. Under the terms of the agreement,. Roche will pay $74 per share for InterMune, which represents a 38% premium to the California-based company's Friday closing price. Monday morning, the healthcare sector proved to be a source of strength for the market. High Related Markets. It is Roche's largest acquisition since it purchased the 40% of Genentech it did not already own for $47 billion in 2009. . InterMune ( ITMN.DL) was health care's top performing stock, thanks to positive phase 3 trial results for its lead drug Esbriet in idiopathic pulmonary fibrosis. InterMune's Shares of Burger King Worldwide . InterMune has a drug, pirfenidone, that treats deadly scarring of the lungs, also known as idiopathic pulmonary fibrosis. This acquisition includes patent rights that InterMune had been licensing from Marnac and KDL as well as other international IP rights relating to pirfenidone that were not part of the prior existing license agreement.
Kourtney Kardashian Wedding Theme, Sensitivity Python Sklearn, Norwin High School Clubs, Uspto Design Database, Alx Software Engineering Syllabus, Twelve Berkeley Glassdoor, Insecticide Poisoning Treatment,